In the evolving renal replacement therapy (RRT) market, key drivers like policy changes, technological advancements, and shifting care models are reshaping the landscape. In this interview, our in-house expert Akash Nayak Karopadi discusses the current state of the global RRT market, its future direction, and the challenges and opportunities for stakeholders. From the rise of home dialysis to the impact of regulatory and economic pressures, Akash highlights what decision-makers need to consider in navigating these changes to create continuity of care for patients. 

What is the status of the current global RRT market?

The global RRT market is valued at around $100 billion. Extracorporeal therapies, including hemodialysis and continuous RRT, account for about 75% of the market. Non-extracorporeal options, like peritoneal dialysis, represent the remaining 25% and are growing, particularly for home-based care and in emerging markets.

In-center dialysis still dominates, with about 80% of the market share, but home dialysis, while now at 20%, is growing quickly. This shift is driven by evolving policies, cost efficiencies, better home dialysis technologies, and the decentralization of care.

Geographically, the United States (US) leads with 40% of the global market, followed by Japan, Germany, and China.

How is the renal replacement therapy market evolving?

The RRT market is transforming rapidly, shaped by policy shifts, economic pressures, and clinical innovation. Home dialysis is central to this shift; no longer a niche option, it is becoming a standard.

In the US, initiatives like the Advancing American Kidney Health Initiative and the End-Stage Renal Disease Treatment Choices Model have pushed the focus toward home dialysis, encouraging providers to move away from centralized care models. Globally, the pandemic exposed the limitations of in-center dialysis, speeding up demand for more flexible and resilient home-based care.

At the same time, rising healthcare costs, especially across Europe, have pushed payers to look for scalable, cost-effective alternatives. Traditional facility-based models are becoming harder to sustain due to supply chain issues and shifting reimbursement structures.

That said, the transition to home dialysis has its challenges. For example, Hurricane Helene in the US highlighted the risks tied to home-based systems that depend on power and connectivity. These kinds of events have led to some regional slowdowns in adoption.

What are the biggest risks for this market over the next 12–24 months?

Over the next year or two, there are a few key areas of risk to watch, especially when it comes to the rise of home dialysis.

On the regulatory side, both the US and Europe are facing headwinds. In the European Union, the Medical Device Regulation is adding complexity for manufacturers. And in the US, the Food and Drug Administration’s downsizing could slow the approval process for new home dialysis technologies. Even though payers are leaning toward home therapies to manage costs, tight budgets might limit how fast infrastructure can scale to support that shift.

Supply chain fragility is another risk point. The market faces shortages in plastic components, fluid production delays, and transportation issues. If trade tensions with China increase, new tariffs could drive up manufacturing costs because many components come from Chinese suppliers.

And finally, labor shortages are a real concern, especially for trained dialysis nurses and technicians. This could hold back the expansion of home dialysis, which depends heavily on skilled support and training.

How can strategic decision-makers and stakeholders in medtech companies in this market prioritize patients?

We advise focusing on a few key areas to center patient needs in this shifting market. Expanding home dialysis access should remain a top priority; companies will want to invest in education, simplify training, and improve remote monitoring. Dedicated transition teams can help reduce dropout rates.

Addressing workforce shortages in dialysis is critical, and medtech companies can drive impact by fostering innovations that make training easier, automate routine tasks, and support multidisciplinary care models. Solutions like smart dialysis machines with automated setup and monitoring, remote patient management platforms, and predictive analytics for patient deterioration can significantly ease staff burden. Enhancing care coordination through interoperable electronic health record modules, real-time data sharing, and digital care planning tools is essential for ensuring seamless, high-quality dialysis care across settings.

Beyond clinical care, expanding psychosocial support, financial counseling, and transportation services can reduce barriers to care. Culturally relevant patient education and peer mentorship programs can also support patients. Finally, promoting value-based payment models that prioritize outcomes will align incentives and encourage flexible, patient-centered care.